Loading clinical trials...

COMPLETED

A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients

A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Surgeries in the Chinese Early-stage Patients With Non-small Cell Lung Cancer

NCT03429673•China-Japan Friendship Hospital

View on ClinicalTrials.gov

Summary

The trial was designed to compare effectiveness and safety of surgeries in the patients with non-small cell lung cancer

Detailed Description

The trial is a multi-centre, real-world, non-interventional, observational study. The Chinese elderly pathologically diagnosed patients with early-stage non-small cell lung cancer enrolled from 2015 to 2017 who received lobectomy or segment/wedge dissection were included and the study data on patient demographic/tumor biological characteristics, and clinical treatments were retrospectively collected to evaluate effectiveness and safety of the surgeries.

Eligibility

Age

65 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who received surgeries from 2014 to 2017;
•Patients who received lobectomy or segment/wedge dissection;
•Pathologically diagnosed patients with non-small cell lung cancer;
•Patients with age \>=65 years old.

Exclusion Criteria

•Patients who received neoadjuvant therapy prior to surgery.

Locations (10)

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

China People's Liberation Army Hospital

Beijing, Beijing Municipality, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Tongji Hospital Affiliated to Huaxi Technology University

Wuhan, Hubei, China

Jiangsu Cancer Hospital

Nanjing, Jiangsu, China

Xi'an Tangdu Hospital

Xi'an, Shaanxi, China

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China

Huaxi Hospital Affiliate to Sichuan University

Chengdu, Sichuan, China

Tianjin Chest Hospital

Tianjin, Tianjin Municipality, China

First Hospital Affiliated to Zhejiang University

Hangzhou, Zhejiang, China

Key Dates

Start Date

December 1, 2017

Primary Completion Date

December 1, 2017

Completion Date

March 30, 2018

Last Updated

May 21, 2018

Enrollment

10,885

ACTUAL participants

Conditions

Non-small Cell Lung Cancer

Interventions

Surgeries

PROCEDURE

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

View study

RECRUITINGPHASE3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248

Non-small Cell Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 21, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients

Inclusion Criteria

Exclusion Criteria

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)